Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH)‘s stock had its “buy” rating reaffirmed by equities research analysts at Bloom Burton in a report released on Wednesday, Zacks.com reports.
Shares of TSE AUP traded down C$0.21 during mid-day trading on Wednesday, reaching C$6.82. 14,700 shares of the company traded hands, compared to its average volume of 52,734. Aurinia Pharmaceuticals has a fifty-two week low of C$6.56 and a fifty-two week high of C$10.47. The company has a debt-to-equity ratio of 0.33, a current ratio of 18.98 and a quick ratio of 18.05. The firm has a market cap of $685.69 million and a PE ratio of -9.78. The stock has a fifty day simple moving average of C$7.77 and a 200-day simple moving average of C$8.28.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last posted its quarterly earnings data on Tuesday, August 6th. The company reported C($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of C($0.20) by C($0.03). The company had revenue of C$0.04 million for the quarter, compared to analyst estimates of C$0.07 million. As a group, analysts predict that Aurinia Pharmaceuticals will post -0.59 EPS for the current fiscal year.
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.